|
CME Program and Slide Decks
Thrombosis Scientific Poster Session and Clinical Update
This program provides expert coverage of late breaking trial news and balanced clinical information. The program centers on the evolution of oral anticoagulants, Factor IIa and Factor Xa inhibition, and recent and ongoing clinical trials examining the latest anticoagulant agents. In addition, Jack E. Ansell, MD and Alexander G.G. Turpie, MD, FRCP, FRCPC answer questions from the audience.
After viewing the presentations, please download, complete, and submit the exam and evaluation for CME credit.
 |
 view presentation
Evolution of Oral Anticoagulants
Jack E. Ansell, MD discusses the history of anticoagulants, with emphasis on those that directly inhibit Factor IIa. Presented are recent Phase II and Phase III clinical trial data for dabigatran etexilate; these trials study VTE prophylaxis in total knee replacement and total hip replacement patients. |
 |
view presentation
Factor Xa Inhibition Landscape
Alexander G.G. Turpie, MD, FRCP, FRCPC discusses Factor Xa anticoagulants in development and recent clinical trial data for these agents. Recent clinical trial results are presented for fondaparinux, Ly517717, YM150, betrixaban, apixaban, and rivaroxaban. |
 |
view presentation
Questions and Answers
Jack E. Ansell, MD and Alexander G.G. Turpie, MD, FRCP, FRCPC answer questions from the auduience. |
|
|
